Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun 6;2013(6):CD003296.
doi: 10.1002/14651858.CD003296.pub3.

Retinoids for preventing the progression of cervical intra-epithelial neoplasia

C William Helm  1 , Douglas J Lorenz, Nicholas J Meyer, William W R Rising, Judith L Wulff
Affiliations
Review

Retinoids for preventing the progression of cervical intra-epithelial neoplasia

C William Helm et al. Cochrane Database Syst Rev. .

Abstract

Background: Invasive cervical carcinoma is preceded by a precancerous phase, cervical intra-epithelial neoplasia (CIN), which can be detected on cervical smears and confirmed by colposcopy and biopsy. Moderate and severe cases of intra-epithelial neoplasia (CIN2 and CIN3) are treated mainly with surgery to prevent progression to invasive carcinoma. Medical methods of preventing the progression or inducing the regression of CIN are needed. Retinoids are potent modulators of epithelial cell growth and differentiation that may have potential for the treatment of CIN.

Objectives: To ascertain whether retinoids can cause regression or prevent progression of CIN.

Search methods: We searched the Cochrane Gynaecological Cancer Review Group's Specialised Register and Non-Trials Database, the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2010), and MEDLINE and EMBASE (July 2010).For the 2013 update, the searches were re-run as follows: CENTRAL, Issue 3, 2013; MEDLINE, April, Week 2, 2013; and EMBASE, Week 16, 2013.

Selection criteria: Randomized controlled trials (RCTs) and non-RCTs of retinoids for treating CIN in women.

Data collection and analysis: Two review authors independently assessed trial quality and extracted data from the trials. Adverse effects information was also collected from the trials.

Main results: Five RCTs comparing the efficacy of four different retinoids were identified. Two studies examined the effects on CIN2 and CIN3 of the retinoids N-(4-hydroxyphenyl)retinamide (fenretinide) and 9-cis-retinoic acid (aliretinoin) given orally. Two examined the effect of all-trans-retinoic acid administered topically to the cervix. The fifth study investigated the use of 13-cis-retinoic acid (isotretinoin) given orally to human immunodeficiency virus (HIV)-positive participants with CIN1 and condyloma.Four studies reported no significant effect of retinoids on the progression to higher grades of CIN, and the fifth did not report data on progression. In all studies retinoids had no significant effect on regression of CIN3. Two studies reported that retinoids were associated with regression of CIN2. One reported a greater complete regression of CIN2 over that seen with placebo, which was of borderline statistical significance (odds ratio (OR) 0.5, 95% confidence interval (CI) 0.25 to 1.02). The other study reported a nonsignificant dose-related trend toward increased rates of complete and partial regression compared with placebo. One study reported significantly worse outcomes in women receiving retinoid (OR for regression 6.00, 95% CI 1.00 to 35.91). In general, the retinoid medications were well tolerated.In the 2010 review and in this update, no new studies were identified for inclusion.

Authors' conclusions: The retinoids studied are not effective in causing regression of CIN3 but may have some effect on CIN2. The data on CIN1 are inadequate. Retinoids are not effective in preventing progression of CIN of any grade. At the doses given for the duration of treatment studied, the retinoids were reasonably well tolerated.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1.1
1.1. Analysis
Comparison 1 Regression of CIN2/3 with retinoid versus control, Outcome 1 Complete or partial regression of CIN2/3 at 3‐12 months.
1.2
1.2. Analysis
Comparison 1 Regression of CIN2/3 with retinoid versus control, Outcome 2 Complete regression of CIN2/3 at 9‐27 months.
1.3
1.3. Analysis
Comparison 1 Regression of CIN2/3 with retinoid versus control, Outcome 3 Complete regression of CIN2 at 9‐27 months.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Alvarez 2003 {published data only}
    1. Alvarez RD, Conner MG, Weiss H, Klug PM, Niwas S, Manne U, et al. The efficacy of 9‐cis retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double blind clinical trial. Cancer, Epidemiology, Biomarkers & Prevention 2003;12(2):114‐9. [MEDLINE: ; Ovid UI: 11705848] - PubMed
Follen 2001 {published data only}
    1. Follen M, Atkinson EN, Schottenfeld D, Malpica A, West L, Lippman S, et al. A randomized clinical trial of 4‐hydroxyphenylretinamide for high‐grade squamous intraepithelial lesions of the cervix. Clinical Cancer Research 2001;7(11):3356‐65. [MEDLINE: ; Ovid UI: 11705848] - PubMed
Meyskens 1994 {published data only}
    1. Meyskens FL, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all‐trans‐retinoic acid: a randomized trial. Journal of the National Cancer Institute 1994;86(7):539‐43. [MEDLINE: ] - PubMed
Robinson 2002 {published data only}
    1. Robinson WR, Andersen J, Darragh TM, Kendall MA, Clark R, Maiman M. Isotretinoin for low‐grade cervical dysplasia in human immunodeficiency virus‐infected women. Obstetrics and Gynecology 2002;99(5):777‐84. [MEDLINE: ; Ovid UI: 11978287] - PubMed
Ruffin 2004 {published data only}
    1. Ruffin MT, Bailey JM, Normolle DP, Michael CW, Bieniasz ME, Kmak DC, et al. Low‐dose topical delivery of all‐trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer, Epidemiology, Biomarkers & Prevention 2004;13(12):2148‐52. [MEDLINE: ] - PubMed

References to studies excluded from this review

Ahn 1997 {published data only}
    1. Ahn WS, Lee JM, Namkoong SE, Lee HY, Kim SJ. Effect of retinoic acid on HPV titration and colposcopic changes in Korean patients with dysplasia of the uterine cervix. Journal of Cellular Biochemistry 1997;67 (Suppl 28/29):133‐9. [MEDLINE: ; AN 1998179533] - PubMed
Chen 1987 {published data only}
    1. Chen RD, Wang RZ, Luo HZ, Liu Y, Bao PY, Li XL, et al. Chemoprevention of cancer of the uterine cervix‐‐preliminary study on the intervention of the cervical precancerous lesion by retinamide RII. Chung‐Hua Chung Liu Tsa Chih 1987;9(5):348‐50. [MEDLINE: ] - PubMed
Chen 1994 {published data only}
    1. Chen RD, Ding AH, Han R, Luo HZ, Fei LF, Sun SF, et al. A study on chemoprevention of retinamide II for cervical precancerous lesions. Chung‐Hua Yu Fang i Hsueh Tsa Chih 1994;28(5):75‐7. [MEDLINE: ] - PubMed
Comerci 1997 {published data only}
    1. Comerci JT, Runowicz CD, Fields AL, Romney SL, Palan PR, Kadish AS, et al. Induction of transforming growth factor beta‐1 in cervical intraepithelial neoplasia in vivo after treatment with beta‐carotene. Clinical Cancer Research 1997;3(2):157‐60. [MEDLINE: ] - PubMed
DiSilvestro 2001 {published data only}
    1. DiSilvestro PA, DiSilvestro JM, Lernhardt W, Pfahl M, Mannel RS. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid‐related molecule. Journal of Lower Genital Tract Disease 2001;5(1):33‐7. [PMID: 17043560] - PubMed
Graham 1986 {published data only}
    1. Graham V, Surwit ES, Weiner S, Meyskens FL Jr. Phase II trial of beta‐all‐trans‐retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. Western Journal of Medicine 1986;145(2):192‐5. [MEDLINE: ] - PMC - PubMed
Han 1990 {published data only}
    1. Han J, Jiao L, Lu Y, Sun Z, Gu QM, Scanlon KJ. Evaluation of N‐4‐(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 1990;4(3):153‐60. [MEDLINE: ] - PubMed
Han 1993 {published data only}
    1. Han J. Highlights of the cancer chemoprevention studies in China. Preventive Medicine 1993;22(5):712‐22. [PMID: 8234211] - PubMed
Kelloff 1995 {published data only}
    1. Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, et al. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Journal of Cellular Biochemistry 1995;23 (Suppl):1‐9. [MEDLINE: ] - PubMed
Kim 2005 {published data only}
    1. Kim HG, Yamal JM, Xu XC, Hu W, Boiko I, Linares A, et al. Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4‐HPR chemoprevention trial. Gynecologic Oncology 2005;99(3 Suppl 1):S32‐7. [MEDLINE: ] - PubMed
Meyskens 1983 {published data only}
    1. Meyskens FL, Graham V, Chvapil M, Dorr RT, Alberts DS, Surwit EA. A phase I trial of beta‐all‐trans‐retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. Journal of the National Cancer Institute 1983;71(5):921‐5. [MEDLINE: ] - PubMed
Meyskens 1986 {published data only}
    1. Meyskens FL Jr, Surwit ES. Clinical experience with topical tretinoin in the treatment of cervical dysplasia. Journal of the American Academy of Dermatology 1986;15(4 part 2):826‐9. [MEDLINE: ] - PubMed
Mitchell 1995 {published data only}
    1. Mitchell MF, Hittelman WN, Lotan R, Nishioka K, Tortolero‐Luna G, Richards‐Kortum R, et al. Chemoprevention trials in the cervix: design, feasibility, and recruitment, [Review]. Journal of Cellular Biochemistry 1995;23 (Suppl):104‐12. [MEDLINE: ] - PubMed
Palan 1988 {published data only}
    1. Palan PR, Basu J, Romney SL. Vaginal hydrolysis of retinyl acetate: increase in plasma retinol and retinol binding protein in women with cervical dysplasias. Biochemical Medicine & Metabolic Biology 1988;40(3):282‐90. [MEDLINE: ] - PubMed
Peng 1986 {published data only}
    1. Peng YM, Alberts DS, Graham V, Surwit EA, Weiner S, Meyskens FL. Cervical tissue uptake of all‐trans‐retinoic acid delivered via a collagen sponge‐cervical cap delivery device in patients with cervical dysplasia. Investigational New Drugs 1987;4(3):245‐9. [MEDLINE: ] - PubMed
Rui 1997 {published data only}
    1. Rui H. Research and development of cancer chemopreventive agents in China [Review]. Journal of Cellular Biochemistry 1997;27 (Suppl):7‐11. [MEDLINE: ] - PubMed
Ruidi 1997 {published data only}
    1. Ruidi C, Aihua D, Peiyu B, Zhongru G, Huazao L, Shifeng S, et al. Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions. Journal of Cellular Biochemistry 1997;28‐29 (Suppl):140‐3. [MEDLINE: ] - PubMed
Sopracordevole 1993 {published data only}
    1. Sopracordevole F, Campagnutta E, Parin A, Scarabelli C. The transretinoic acid in the treatment of cervical intraepithelial neoplasia. The Cervix and the Lower Female Genital Tract 1993; Vol. 11, issue 1:33‐4. [AN 1993154840]
Surwit 1982 {published data only}
    1. Surwit EA, Graham V, Droegemueller W, Alberts D, Chvapil M, Dorr RT, et al. Evaluation of topically applied trans‐retinoic acid in the treatment of cervical intraepithelial lesions. American Journal of Obstetrics & Gynecology 1982;143(7):821‐3. [MEDLINE: ] - PubMed
Weiner 1986 {published data only}
    1. Weiner SA, Surwit EA, Graham VE, Meyskens FL Jr. A phase I trial of topically applied trans‐retinoic acid in cervical dysplasia‐clinical efficacy. Investigational New Drugs 1986;4(3):241‐4. [MEDLINE: ] - PubMed
Ziegler 1986 {published data only}
    1. Ziegler RG. Epidemiologic studies of vitamins and cancer of the lung, esophagus, and cervix. Advances in Experimental Medicine & Biology 1986;206:11‐26. [MEDLINE: ] - PubMed

Additional references

Altucci 2001
    1. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nature Reviews Cancer 2001;1(3):181‐93. [MEDLINE: ] - PubMed
Behbakht 1996
    1. Behbakht K, DeGeest K, Turyk ME, Wilbanks GD. All‐trans‐retinoic acid inhibits the proliferation of cell lines derived from human cervical neoplasia. Gynecologic Oncology 1996;61(1):31‐9. [MEDLINE: ] - PubMed
Bollag 1992
    1. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Annals of Oncology 1992;3(7):513‐26. [MEDLINE: ] - PubMed
Brtko 2003
    1. Brtko J, Thalhamer J. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Current Pharmaceutical Design 2003;9(25):2067‐77. [MEDLINE: ] - PubMed
Choo 1995
    1. Choo CK, Rorke EA, Eckert RL. Retinoid regulation of cell differentiation in a series of human papillomavirus type 16‐immortalized human cervical epithelial cell lines. Carcinogenesis 1995;16(2):375‐81. [MEDLINE: ] - PubMed
Follen 2002
    1. Follen M, Vlastos A‐T, Meyskens FL Jr, Atkinson N, Schottenfeld D. Why Phase II trials in cervical chemoprevention are negative: what have we learned?. Cancer Causes and Control 2002;13(9):855‐73. [MEDLINE: ] - PubMed
Geisen 1997
    1. Geisen C, Denk C, Gremm B, Baust C, Karger A, Bollag W. High‐level expression of the retinoic acid receptor beta gene in normal cells of the uterine cervix is regulated by the retinoic acid receptor alpha and is abnormally down‐regulated in cervical carcinoma cells. Cancer Research 1997;57(8):1460‐7. [MEDLINE: ] - PubMed
Goodman 1984
    1. Goodman DS. Vitamin A and retinoids in health and disease. New England Journal of Medicine 1984;310(16):1023‐31. [MEDLINE: ] - PubMed
Grace 2006
    1. Grace VMB, Devaraj NS, Pillai R, Devaraj H. HPV‐induced carcinogenesis of the uterine cervix is associated with reduced serum ATRA level. Gynecologic Oncology 2006;103(1):113‐9. [MEDLINE: ] - PubMed
Higgins 2009
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org.
Hong 1986
    1. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13‐Cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine 1986;315:1501‐5. [MEDLINE: ] - PubMed
Hong 1990
    1. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS. Prevention of second primary tumors with isotretinoin in squamous‐cell carcinoma of the head and neck. New England Journal of Medicine 1990;323:795‐801. [MEDLINE: ] - PubMed
La Vecchia 1988
    1. Vecchia C, Decarli A, Fasoli M, Parazzini F, Franceschi S, Gentile A, et al. Dietary vitamin A and the risk of intraepithelial and invasive cervical neoplasia. Gynecologic Oncology 1988;30(2):187‐95. [MEDLINE: ] - PubMed
Liu 1995
    1. Liu T, Soong SJ, Alvarez RD, Butterworth CE Jr. A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. Cancer Epidemiology, Biomarkers & Prevention 1995;4(4):373‐80. [MEDLINE: ] - PubMed
Lotan 1980
    1. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochimica et Biophysica Acta 1980;605(1):33‐91. [MEDLINE: ] - PubMed
McCance 1988
    1. McCance DJ, Kopan R, Fuchs E, Laimins LA. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proceedings of the National Academy of Sciences of the United States of America 1988;85(19):7169‐73. [MEDLINE: ] - PMC - PubMed
Mills 1993
    1. Mills CM, Marks R. Adverse reactions to oral retinoids: an update. Drug Safety 1993;9(4):280‐90. - PubMed
Nagata 1999
    1. Nagata C, Shimizu H, Higashiiwai H, Sugahara N, Morita N, Komatsu S, et al. Serum retinol level and risk of subsequent cervical cancer in cases with cervical dysplasia. Cancer Investigation 1999;17(4):253‐8. [MEDLINE: ] - PubMed
Niles 2000
    1. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. [see comment]. Nutrition 2000;16(11‐12):1084‐9. [MEDLINE: ] - PubMed
Parkin 2006
    1. Parkin DM. The global health burden of infection‐associated cancers in the year 2002. International Journal of Cancer 2006;118(12):3030‐44. [MEDLINE: ] - PubMed
Potischman 2003
    1. Potischman N, Freudenheim JL. Biomarkers of nutritional exposure and nutritional status: an overview. Journal of Nutrition 2003;133(3):873S‐4S. [MEDLINE: ] - PubMed
Ribeiro 1995
    1. Ribeiro RC, Kushner PJ, Baxter JD, Kushner PJ, Baxter JD. The nuclear hormone receptor gene superfamily. Annual Review of Medicine 1995;46:443‐53. [MEDLINE: ] - PubMed
Schimizu 1996
    1. Shimizu H, Nagata C, Komatsu S, Morita N, Higashiiwai H, Sugahara N, et al. Decreased serum retinol levels in women with cervical dysplasia. British Journal of Cancer 1996;73(12):1600‐4. [MEDLINE: ] - PMC - PubMed
Soprano 1995
    1. Soprano DR, Soprano KJ. Retinoids as teratogens. Annual Review of Nutrition 1995;15:111‐32. [PMID: 8527214] - PubMed
Sporn 1984
    1. Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. Journal of the National Cancer Institute 1984;73(6):1381‐7. [MEDLINE: ] - PubMed
Sun 2002
    1. Sun S‐Y, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Critical Reviews in Oncology/Hematology 2002;41(1):41‐55. [MEDLINE: ] - PubMed
Zanardi 2006
    1. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer prevention. Endocrine‐Related Cancer 2006;13(1):51‐68. [MEDLINE: ] - PubMed

MeSH terms